A Study Examining the Use of a Migraine Medicine in the Treatment of Two Migraine Attacks in Patients Who Have Increased Skin Sensitivity

Inclusion Criteria: * Male and female subjects between the ages of 18 and 65, inclusive * Subjects diagnosed with episodic migraine, with or without aura according to International Headache Criteria (IHS) (Appendix B) for at least one-year prior to screening * Subjects who experience between 3-10 migraine attacks per month (during the previous 6 months) with no more than 15 days of headache per month. * Subjects who report their migraine pain quality as pulsating/ throbbing. * Subject is using or agrees to use for the duration of participation a medically acceptable form of contraception (as determined by investigator), if female of child-bearing potential * Subjects who are able to come for 2-hour in-clinic treatment of two separate migraine attacks * Subjects who are able to understand and comply with all study procedures. * Subject provides written informed consent prior to any screening procedures being conducted Exclusion Criteria: * Pregnant and/or lactating women * Subjects who, in the investigators opinion, have a history or have evidence of a medical or psychiatric condition that would expose them to an increased risk of a significant adverse event or would interfere with the assessments of efficacy and tolerability during this trial * Subjects with an abnormal ECG that, in the investigators opinion, would expose them to increased risk of adverse events or interfere with study drug and/or analysis of efficacy/tolerability * Subjects currently using, or expecting to use during the trial, Cytochrome P450 3A4 (CYP3A4 enzymes) inhibitors (such as protease inhibitors and macrolide antibiotics) * Subjects with severely impaired hepatic or renal function, as determined by the investigator * Subjects who have participated in an investigational drug trial in the 30 days prior to the screening visit * Subjects who currently have or have a history of basilar or hemiplegic migraine * Subjects who have previously shown hypersensitivity to ergot alkaloids * Subjects who have a history of non-response to DHE-45, as determined by investigator * Subjects with uncontrolled hypertension * Subjects who currently have or who have a history of ischemia and/or vasospastic coronary artery disease * Subjects who, in the investigators opinion, have significant risk factors of coronary artery disease